Agios Pharmaceuticals, Inc.
NASDAQ:AGIOBiotechnology
+$0.50 today
- Market cap
- $1.72B
- Beta
- 0.59
- P/E (TTM)
- -4.7
- EPS (TTM)
- -$7.19
Volume 0.47M
Average 1.11M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Agios Pharmaceuticals, Inc.
NASDAQ:AGIO
Intrinsic Alpha fair value
Locked
Current Price
$28.76
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | +56.0% | +72.2% (5yr)6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Recent growth has been strongest in Revenue at +56.0% over three years. Forward estimates point to Revenue at +72.2% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Mirum Pharmaceuticals, Inc. NASDAQ:MIRM | $6.14B | $93.99 | Undervalued | -7.8 | +38.10% |
PTC Therapeutics, Inc. NASDAQ:PTCT | $5.30B | $63.49 | Undervalued | -35.0 | -23.72% |
Disc Medicine, Inc. NASDAQ:IRON | $3.07B | $80.00 | Not rated | -11.2 | -15.76% |
BioCryst Pharmaceuticals, Inc. NASDAQ:BCRX | $1.96B | $7.61 | Undervalued | -4.8 | +4.13% |
Ultragenyx Pharmaceutical Inc. NASDAQ:RARE | $1.64B | $16.08 | Not rated | -4.6 | -44.77% |
Pharming Group N.V. NASDAQ:PHAR | $891.80M | $12.60 | Not rated | 77.0 | -25.11% |
Continue the stock analysis
Jump to another research area for this company.